Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline Review, H2 2015

Date: October 30, 2015
Pages: 104
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: F6A4A848946EN
Leaflet:

Download PDF Leaflet

Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline Review, H2 2015’, provides an overview of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Overview
Therapeutics Development
Pipeline Products for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Overview
Pipeline Products for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Comparative Analysis
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Therapeutics under Development by Companies
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Therapeutics under Investigation by Universities/Institutes
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Products under Development by Companies
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Products under Investigation by Universities/Institutes
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Companies Involved in Therapeutics Development
Aegerion Pharmaceuticals, Inc.
Cerenis Therapeutics Holding SA
CymaBay Therapeutics, Inc.
Gemphire Therapeutics Inc.
Merck & Co., Inc.
Pfizer Inc.
Regeneron Pharmaceuticals, Inc.
RegenxBio Inc.
Sanofi
Thetis Pharmaceuticals LLC
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(ezetimibe + atorvastatin calcium) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AEM-28 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AEM-28-02 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AEM-2814 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
alirocumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AM-0010 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
anacetrapib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Antisense Oligonucleotides to Inhibit ApoB100 for Familial Hypercholesterolemia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bococizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BSN-272 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CER-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
evinacumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
gemcabene calcium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lomitapide mesylate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MBX-8025 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
mipomersen sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RGX-501 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TP-452 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Recent Pipeline Updates
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Dormant Projects
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Discontinued Products
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Product Development Milestones
Featured News & Press Releases
Sep 01, 2015: Sanofi And Regeneron Announce New Positive Praluent Phase 3 Data Presented At Esc Congress 2015
Aug 03, 2015: Isis Reports Positive Data from KYNAMRO (mipomersen sodium) FOCUS FH Phase 3 Study in Patients with Severe Heterozygous Familial Hypercholesterolemia
Jul 24, 2015: Sanofi And Regeneron Announce FDA Approval Of Praluent (Alirocumab) Injection, The First Pcsk9 Inhibitor In The U.S., For The Treatment Of High LDL Cholesterol In Adult Patients
May 26, 2015: Aegerion Pharmaceuticals Achieves Primary Endpoint in Phase III Study of Lomitapide in Japanese Patients With Homozygous Familial Hypercholesterolemia (HoFH)
Apr 30, 2015: AOP Orphan Launches Lojuxta (lomitapide) for Treatment of Homozygous Familial Hypercholesterolaemia to the Austrian Market
Apr 23, 2015: CymaBay Therapeutics Announces the Initiation of a Phase 2 Study of MBX-8025 in Patients With Homozygous Familial Hypercholesterolemia
Mar 25, 2015: CymaBay Therapeutics Announces U.S. Orphan Drug Designation for MBX-8025 in Homozygous Familial Hypercholesterolemia
Jan 28, 2015: Aegerion Investigated by Former Louisiana Attorney General and Special Prosecutor Richard P. Ieyoub and the Firm of Ieyoub O’Bell & Myers
Nov 18, 2014: Genzyme And Isis Present KYNAMRO Clinical Data At The American Heart Association
Sep 02, 2014: Isis Pharmaceuticals Presents Data On KYNAMRO At European Society of Cardiology Congress 2014
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia), H2 2015
Number of Products under Development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd...1)
Products under Investigation by Universities/Institutes, H2 2015
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline by Aegerion Pharmaceuticals, Inc., H2 2015
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline by Cerenis Therapeutics Holding SA, H2 2015
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline by CymaBay Therapeutics, Inc., H2 2015
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline by Gemphire Therapeutics Inc., H2 2015
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline by Merck & Co., Inc., H2 2015
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline by Pfizer Inc., H2 2015
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline by Regeneron Pharmaceuticals, Inc., H2 2015
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline by RegenxBio Inc., H2 2015
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline by Sanofi, H2 2015
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline by Thetis Pharmaceuticals LLC, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics - Recent Pipeline Updates, H2 2015
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Dormant Projects, H2 2015
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Discontinued Products, H2 2015

LIST OF FIGURES

Number of Products under Development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia), H2 2015
Number of Products under Development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Molecule Types, H2 2015
Number of Products by Stage and Molecule Types, H2 2015

COMPANIES MENTIONED

Aegerion Pharmaceuticals, Inc.
Cerenis Therapeutics Holding SA
CymaBay Therapeutics, Inc.
Gemphire Therapeutics Inc.
Merck & Co., Inc.
Pfizer Inc.
Regeneron Pharmaceuticals, Inc.
RegenxBio Inc.
Sanofi
Thetis Pharmaceuticals LLC
Skip to top


Hypercholesterolemia - Pipeline Review, Q4 2010 US$ 500.00 Dec, 2010 · 60 pages
Hypercholesterolemia - Pipeline Review, Q1 2011 US$ 500.00 Mar, 2011 · 58 pages
Hypercholesterolemia - Pipeline Review, H2 2015 US$ 2,000.00 Dec, 2015 · 236 pages

Ask Your Question

Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: